 |
Return Create A Forum - Home |
 |
--------------------------------------------------------- |
|
MS Speaks |
 |
https://msspeaks.createaforum.com |
|
--------------------------------------------------------- |
|
***************************************************** |
|
Return to: OCREVUS (ocrelizumab) |
|
***************************************************** |
|
#Post#: 2989-------------------------------------------------- |
|
(Abst.) Switching to Ocrevus in RRMS patients at risk of PML pre |
|
viously treated w/EID Tysabri |
|
By: agate Date: August 7, 2020, 6:51 pm |
|
--------------------------------------------------------- |
|
From PubMed (August 7, 2020)--"Switching to ocrelizumab in RRMS |
|
patients at risk of PML previously treated with extended |
|
interval dosing of natalizumab": |
|
https://pubmed.ncbi.nlm.nih.gov/32749910/ |
|
***************************************************** |
